Obesity is a global health issue with rising prevalence, leading to increased morbidity, mortality, and healthcare costs. It is closely linked to metabolic syndrome, which includes conditions like coronary artery disease, hypertension, type 2 diabetes, and dyslipidemia. Obesity increases cardiovascular risk through factors such as elevated triglycerides, low HDL cholesterol, and high blood pressure. Dyslipidemia in obesity is characterized by increased triglycerides, small dense LDL, and low HDL, often due to hepatic overproduction of apoB-containing lipoproteins. Insulin resistance in peripheral tissues contributes to dyslipidemia by increasing fatty acid flux and impairing lipid metabolism. Postprandial lipemia and free fatty acid dynamics play a key role in this process. The review discusses lipid metabolism in obesity, focusing on postprandial lipemia, FFA dynamics, and potential interventions. It highlights the importance of lifestyle changes, including weight loss, exercise, and dietary modifications, in managing dyslipidemia. Pharmacological treatments such as statins, fibrates, and omega-3 fatty acids are also discussed. The review emphasizes the need for targeted therapies, including apoB and non-HDL-C levels, as more accurate markers of atherogenic risk in obesity. The role of inflammation and the complement system in lipid metabolism is also explored. Overall, the review underscores the complex interplay between obesity, lipid metabolism, and cardiovascular disease, highlighting the importance of integrated approaches for effective management of dyslipidemia in obesity.Obesity is a global health issue with rising prevalence, leading to increased morbidity, mortality, and healthcare costs. It is closely linked to metabolic syndrome, which includes conditions like coronary artery disease, hypertension, type 2 diabetes, and dyslipidemia. Obesity increases cardiovascular risk through factors such as elevated triglycerides, low HDL cholesterol, and high blood pressure. Dyslipidemia in obesity is characterized by increased triglycerides, small dense LDL, and low HDL, often due to hepatic overproduction of apoB-containing lipoproteins. Insulin resistance in peripheral tissues contributes to dyslipidemia by increasing fatty acid flux and impairing lipid metabolism. Postprandial lipemia and free fatty acid dynamics play a key role in this process. The review discusses lipid metabolism in obesity, focusing on postprandial lipemia, FFA dynamics, and potential interventions. It highlights the importance of lifestyle changes, including weight loss, exercise, and dietary modifications, in managing dyslipidemia. Pharmacological treatments such as statins, fibrates, and omega-3 fatty acids are also discussed. The review emphasizes the need for targeted therapies, including apoB and non-HDL-C levels, as more accurate markers of atherogenic risk in obesity. The role of inflammation and the complement system in lipid metabolism is also explored. Overall, the review underscores the complex interplay between obesity, lipid metabolism, and cardiovascular disease, highlighting the importance of integrated approaches for effective management of dyslipidemia in obesity.